Literature DB >> 1255496

Stereospecific radioimmunoassay for propranolol isomers.

K Kawashima, A Levy, S Spector.   

Abstract

Antisera against propranolol were produced in rabbits immunized with propranolol conjugated to bovine serum albumin. The antiserum against dl-propranolol recognized both d- and l-propranolol to the same degree. However, antiserum against l-propranolol was able to discriminate the l-propranolol selectively. The antisera were used to develop radioimmunoassays for dl-propranolol and l-propranolol. The assay can detect as little as 10 pg of propranolol. Metabolites of propranolol do not interfere with the assay unless concentrations are very high. Serum and heart levels of l-propranolol and the d-isomer were determined in the rat after i.v. injection (1 mg/kg) of dl-propranolol. l-Propranolol declines rapidly in the blood after the injection. Concomitantly, there is a rapid accumulation of l-propranolol by the heart. The d-form of propranolol remains in the blood and is metabolized rapidly as reflected by a shorter half-life (23.8 minutes) than the one found for l-propranolol (5.20 minutes).

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1255496

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  16 in total

Review 1.  Stereoselectivity in clinical pharmacokinetics and drug development.

Authors:  D B Campbell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

Review 2.  Chirality. Clinical pharmacokinetic and pharmacodynamic considerations.

Authors:  E J Lee; K M Williams
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

Review 3.  Stereoselectivity of antibodies for the bioanalysis of chiral drugs.

Authors:  P A Got; J M Scherrmann
Journal:  Pharm Res       Date:  1997-11       Impact factor: 4.200

4.  Circadian influence on effect of propranolol on exercise-induced tachycardia in healthy subjects.

Authors:  A Fujimura; Y Kumagai; K Sugimoto; H Nakashima; H Kajiyama; A Ebihara; K Ohashi
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 5.  Importance of drug enantiomers in clinical pharmacology.

Authors:  K Williams; E Lee
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

6.  Clinical pharmacology of a new beta-adrenoceptor blocking drug, befunolol. Cross-over comparison with propranolol on repeated administration.

Authors:  A Ebihara; K Tawara; T Oka; T Ofuji; K Kawahara
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

8.  Antibodies raised against purified beta-adrenergic receptors specifically bind beta-adrenergic ligands.

Authors:  M G Caron; Y Srinivasan; R Snyderman; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1979-05       Impact factor: 11.205

9.  Comparison of radioreceptor assay and radioimmunoassay for atropine: pharmacokinetic application.

Authors:  L Aaltonen; J Kanto; E Iisalo; K Pihlajamäki
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

10.  Plasma levels of (+) and (-)-propranolol and 4-hydroxypropranolol after administration of racemic (+/-)-propranolol in man.

Authors:  C Von Bahr; J Hermansson; K Tawara
Journal:  Br J Clin Pharmacol       Date:  1982-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.